万邦德制药集团浙江医药销售有限公司

Why it is here

State Administration for Market Regulation of China — antitrust (SAMR and provincial AMRs, samr.gov.cn) — abuse of a dominant market position (反垄断局浙江省市场监督管理局 · 市场监管总局发布万邦德制药集团浙江医药销售有限公司滥用市场支配地位案行政处罚决定书), from 17 November 2020.

State Administration for Market Regulation of China — antitrust (SAMR and provincial AMRs, samr.gov.cn) — Abuse of a dominant market position.

Details

Company

万邦德制药集团浙江医药销售有限公司

Authority

State Administration for Market Regulation of China — antitrust (SAMR and provincial AMRs, samr.gov.cn)

Decision

Abuse of a dominant market position

Grounds and details, as published

反垄断局浙江省市场监督管理局 · 市场监管总局发布万邦德制药集团浙江医药销售有限公司滥用市场支配地位案行政处罚决定书

From

17 November 2020

Until

—

Status

End date not published

Source

https://www.samr.gov.cn/fldys/tzgg/xzcf/art/2023/art_b3bbcad9d44d4c418f002817aa6da2cb.html

Licence

Public antitrust decisions published by the State Administration for Market Regulation of China (samr.gov.cn/fldys)